NCT00381810 - A Study to Evaluate the Safety of Rituximab Retreatment in Subjects With Systemic Lupus Erythematosus | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 22, 2006

Primary Completion Date

July 31, 2008

Study Completion Date

February 29, 2012

Conditions

Lupus Erythematosus, Systemic

Interventions

DRUG

Rituximab

Rituximab will be supplied as a liquid for intravenous infusion.

DRUG

Methylprednisolone

DRUG

Acetaminophen

DRUG

Diphenhydramine

Trial Locations (11)

North Shore - Long Island Jewish Hospital Health System; Rheumatology & Allergy- Clinical Immunology, Great Neck

Medical Univ of South Carolina, Charleston

University of Chicago, Chicago

University of Kansas Medical Center, Kansas City

Oklahoma Medical Research Foundation, Oklahoma City

Texas Research Center, Sugar Land

Intermountain Research Center, Boise

Coeur D'Alene Arthritis Clinic, Coeur d'Alene

Arizona Arthritis & Rheumatology Research, Pllc, Paradise Valley

Eden Medical Center San Leandro Hospital, San Leandro

Seattle Rheumatology Assoc; Swedish Rheumatology Research, Seattle